Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec Forms China Cancer Immunotherapy JV with Juno Therapeutics

publication date: Apr 8, 2016
WuXi AppTec, China's largest CRO/CMO, and Juno Therapeutics of Seattle have formed a 50-50 joint venture to bring Juno's promising immuno-oncology drugs to China. The new company, JW Biotechnology, will be based in Shanghai and will eventually own China rights to Juno's products, once certain unspecified conditions are met. Juno will be paid an upfront payment in equity (presumably JV equity), plus milestone payments and royalties on sales. WuXi will use its CRO capabilities to pursue China approval of the products. Through its venture arm, WuXi has already invested in Juno. More details....

Stock Symbol: (NSDQ: JUNO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital